Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 3 for:    mcguff
Previous Study | Return to List | Next Study

A Pharmacokinetics Study of Intravenous Ascorbic Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02534753
Recruitment Status : Completed
First Posted : August 28, 2015
Last Update Posted : March 23, 2016
Information provided by (Responsible Party):
McGuff Pharmaceuticals, Inc.

Brief Summary:
This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Drug: Ascor L 500® (Ascorbic Acid Injection, USP) Phase 1

Detailed Description:

The objectives of this study are:

  1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV).
  2. To evaluate the safety and tolerability of AA administered intravenously.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers
Study Start Date : September 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin C

Arm Intervention/treatment
Experimental: Single Group Drug: Ascor L 500® (Ascorbic Acid Injection, USP)
A sterile, solution containing 500 mg ascorbic acid per mL
Other Name: Ascorbic Acid

Primary Outcome Measures :
  1. Concentration of Ascorbic Acid (µM) in plasma [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system [ Time Frame: 1 day ]
  2. Changes from Baseline in clinical laboratory and vital signs to discharge [ Time Frame: 1 day ]
  3. Changes from pre-dose physical exam findings to discharge [ Time Frame: 1 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Is between the ages of 18 and 45 years, inclusive.
  • Has a body mass index (BMI) between 18 and 32 kg/m2.
  • Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures.

Exclusion Criteria:

  • Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid
  • Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid
  • Has participated in an investigational drug study within the 30 days prior to CRU admission.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02534753

Layout table for location information
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23284
Sponsors and Collaborators
McGuff Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Damon P Jones, BS/MBA McGuff Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: McGuff Pharmaceuticals, Inc. Identifier: NCT02534753    
Other Study ID Numbers: MGP-101
First Posted: August 28, 2015    Key Record Dates
Last Update Posted: March 23, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Ascorbic Acid
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Growth Substances